{
    "eid": "2-s2.0-85021858117",
    "title": "Persistence of wild-type Japanese encephalitis virus strains cross-neutralization 5 years after JE-CV immunization",
    "cover-date": "2017-01-15",
    "subject-areas": [
        {
            "$": "Immunology and Allergy",
            "@code": "2723"
        },
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        }
    ],
    "keywords": [
        "Genotypes",
        "Japanese encephalitis vaccines",
        "Long-Term protection",
        "Wild-Type strains; cross-neutralization"
    ],
    "authors": [
        "Emmanuel Feroldi"
    ],
    "citedby-count": 16,
    "ref-count": 31,
    "ref-list": [
        "Emerging flaviviruses: The spread and resurgence of japanese encephalitis, west nile and dengue viruses",
        "New initiatives for the control of Japanese encephalitis by vaccination: Minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998",
        "Estimated global incidence of Japanese encephalitis: A systematic review",
        "Japanese Encephalitis Vaccines",
        "Health Information for International Travel",
        "Japanese encephalitis vaccines - Needs, flaws and achievements",
        "Phylogenetic analysis suggests only one serotype of Japanese encephalitis virus",
        "Japanese encephalitis vaccines",
        "Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia",
        "Genotype v japanese encephalitis virus is emerging",
        "Emergence of Japanese encephalitis virus genotype v in the Republic of Korea",
        "Shift in Japanese encephalitis virus (JEV) genotype circulating in northern Vietnam: Implications for frequent introductions of JEV from Southeast Asia to East Asia",
        "Change in Japanese encephalitis virus distribution, Thailand",
        "Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes",
        "Partially Neutralizing Potency against Emerging Genotype I Virus among Children Received Formalin-Inactivated Japanese Encephalitis Virus Vaccine",
        "Protection of SA14-14-2 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses",
        "Safety and immunogenicity of a single administration of live-attenuated japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: Multicenter randomized controlled trial",
        "Immune response to live-attenuated Japanese encephalitis vaccine (JE-CV) neutralizes Japanese encephalitis virus isolates from South-East Asia and India",
        "Chimeric Live, Attenuated Vaccine against Japanese Encephalitis (ChimeriVax-JE): Phase 2 Clinical Trials for Safety and Immunogenicity, Effect of Vaccine Dose and Schedule, and Memory Response to Challenge with Inactivated Japanese Encephalitis Antigen",
        "Clinical proof of principle for ChimeriVax\u2122: Recombinant live, attenuated vaccines against flavivirus infections",
        "Yellow fever/Japanese encephalitis chimeric viruses: Construction and biological properties",
        "Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004",
        "Japanese Encephalitis  Vaccines: WHO position paper  \u2013 February 2015",
        "Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: Randomized, controlled phase 3 immunogenicity and safety trial",
        "Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children",
        "Seventh Asian Congress of Pediatric Infectious Disease",
        "Eighth World Congress of TheWorld Society for Pediatric Infectious Diseases",
        "Review on flavivirus vaccine development: Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand",
        "Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax\u2122-JE experimental vaccine",
        "Antigenic characterization of the live attenuated Japanese encephalitis vaccine virus SA14-14-2: a comparison with isolates of the virus covering a wide geographic area",
        "Phylogenetic analysis of the envelope gene of Japanese encephalitis virus"
    ],
    "affiliation": [
        {
            "affiliation-city": "Lyon",
            "affilname": "Sanofi Pasteur SA",
            "affiliation-country": "France"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Siriraj Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "New York",
            "affilname": "International AIDS Vaccine Initiative",
            "affiliation-country": "United States"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Nakhon Pathom",
            "affilname": "Mahidol University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Singapore City",
            "affilname": "Clinical R andD and Medical Affairs",
            "affiliation-country": "Singapore"
        }
    ],
    "funding": [
        "Sanofi Pasteur",
        "Sanofi Pasteur"
    ]
}